Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE®(pegcetacoplan injection) and $91 million for EMPAVELI®(pegcetacoplan) Strong […]
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase […]